AI Summary & Key Takeaways
AI InsightThe progressionfreesurvival (PFS), overall survival (OS) and overall response rate (ORR) differences between SII low and high groupshave investigated The correlation between SII and PFS was also evaluated.Results: Totally, 50 patients enrolled to study.
📌 3 Key Takeaways
Abstract
Objectives: EML4-ALK rearrangement is found in a small group of non-small cell lung cancer (NSCLC). In this patientpopulation, the search of the predictive and prognostic biomarkers have been still continuing. Systemic immune-inflammationindex (SII) is a novel marker for reflection of the inflammatory condition of the human body. So, we aimedthat evaluated the prognostic value of SII in NSCLC with ALK rearrangement.Methods: The patients who diagnosed advanced NSCLC with ALK rearrangement and received crizotinib at any-lineof treatment were enrolled to study. SII was calculated by using formula as follow: (Neutrophil x platelet) / lymphocyte.The cut-off value was accepted as 640 and the patients stratified according to SII level as low and high. The progressionfreesurvival (PFS), overall survival (OS) and overall response rate (ORR) differences between SII low and high groupshave investigated The correlation between SII and PFS was also evaluated.Results: Totally, 50 patients enrolled to study. Twenty-eight of 50 were stratified to SII high group and 22 of 50 to SII lowgroup. Median follow-up time from diagnosis was 25 months. Median PFS was significantly longer in SII low group thanSII high group (24.01 vs. 7.8 months; p=0.024). Overall survival was also significantly longer in SII low group comparewith SII high group (NR vs. 29.08 months; p=0.001). the significantly negative correlation between PFS and SII was alsodetected (r=-0.355; p=0.011).Conclusion: SII, a non-invasive, easily accessible - assessable marker, can be used as a prognostic marker in NSCLC withALK-rearrangement, according to results of our study.